Literature DB >> 16889529

Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices.

Weidong Yang1, Ronald R Gomes, Anissa J Brown, Ashley R Burdett, Michael Alicknavitch, Mary C Farach-Carson, Daniel D Carson.   

Abstract

Extracellular matrix (ECM) molecules in cartilage cooperate with growth factors to regulate chondrogenic differentiation and cartilage development. Domain I of perlecan (Pln) bears heparan sulfate chains that bind and release heparin binding growth factors (HBGFs). We hypothesized that Pln domain I (PlnDI) might be complexed with collagen II (P-C) fibrils to improve binding of bone morphogenetic protein-2 (BMP-2) and better support chondrogenesis and cartilage-like tissue formation in vitro. Our results showed that P-C fibrils bound more BMP-2 than collagen II fibrils alone, and better sustained BMP-2 release. Polylactic acid (PLA)-based scaffolds coated with P-C fibrils immobilized more BMP-2 than either PLA scaffolds or PLA scaffolds coated with collagen II fibrils alone. Multipotential mouse embryonic mesenchymal cells, C3H10T1/2, were cultured on 2-dimensional P-C fibrils or 3-dimensional P-C/BMP-2-coated (P-C-B) PLA scaffolds. Chondrogenic differentiation was indexed by glycosaminoglycan (GAG) production, and expression of the pro-chondrogenic transcription factor, Sox9, as well as cartilaginous ECM proteins, collagen II, and aggrecan. Immunostaining for aggrecan, perlecan, tenascin, and collagen X revealed that both C3H10T1/2 cells and primary mouse embryonic fibroblasts cultured on P-C-B fibrils showed the highest expression of chondrogenic markers among all treatment groups. Safranin O-Fast Green staining indicated that cartilage-like tissue was formed in the P-C-B scaffolds, while no obvious cartilage-like tissue formed in other scaffolds. We conclude that P-C fibrils provide an improved biomimetic material for the binding and retention of BMP-2 and support chondrogenic differentiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16889529      PMCID: PMC1774589          DOI: 10.1089/ten.2006.12.2009

Source DB:  PubMed          Journal:  Tissue Eng        ISSN: 1076-3279


  57 in total

1.  Evaluation of cellular affinity and compatibility to biodegradable polyesters and Type-II collagen-modified scaffolds using immortalized rat chondrocytes.

Authors:  Shan-Hui Hsu; Ching-Lin Tsai; Cheng-Ming Tang
Journal:  Artif Organs       Date:  2002-07       Impact factor: 3.094

2.  Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.

Authors:  Sarah Knox; Catherine Merry; Sally Stringer; James Melrose; John Whitelock
Journal:  J Biol Chem       Date:  2002-02-14       Impact factor: 5.157

3.  In vitro engineered cartilage constructs produced by press-coating biodegradable polymer with human mesenchymal stem cells.

Authors:  Ulrich Nöth; Richard Tuli; Anna M Osyczka; Keith G Danielson; Rocky S Tuan
Journal:  Tissue Eng       Date:  2002-02

4.  Perlecan is essential for cartilage and cephalic development.

Authors:  E Arikawa-Hirasawa; H Watanabe; H Takami; J R Hassell; Y Yamada
Journal:  Nat Genet       Date:  1999-11       Impact factor: 38.330

5.  An improved method to prepare hyaluronic acid and type II collagen composite matrices.

Authors:  Tetsushi Taguchi; Toshiyuki Ikoma; Junzo Tanaka
Journal:  J Biomed Mater Res       Date:  2002-08

6.  Gene expression profiling following BMP-2 induction of mesenchymal chondrogenesis in vitro.

Authors:  M W Izzo; B Pucci; R S Tuan; D J Hall
Journal:  Osteoarthritis Cartilage       Date:  2002-01       Impact factor: 6.576

7.  Cell density dependent regulation of AP-1 activity is important for chondrogenic differentiation of C3H10T1/2 mesenchymal cells.

Authors:  M Reza Seghatoleslami; Rocky S Tuan
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

8.  Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I.

Authors:  Margaret M French; Ronald R Gomes; Rupert Timpl; Magnus Höök; Kirk Czymmek; Mary C Farach-Carson; Daniel D Carson
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

9.  Heparan sulfate proteoglycans retain Noggin at the cell surface: a potential mechanism for shaping bone morphogenetic protein gradients.

Authors:  Stephenie Paine-Saunders; Beth L Viviano; Aris N Economides; Scott Saunders
Journal:  J Biol Chem       Date:  2001-11-12       Impact factor: 5.157

10.  Crosslinked type II collagen matrices: preparation, characterization, and potential for cartilage engineering.

Authors:  J S Pieper; P M van der Kraan; T Hafmans; J Kamp; P Buma; J L C van Susante; W B van den Berg; J H Veerkamp; T H van Kuppevelt
Journal:  Biomaterials       Date:  2002-08       Impact factor: 12.479

View more
  27 in total

1.  Repair of cartilage defects in arthritic tissue with differentiated human embryonic stem cells.

Authors:  Tsaiwei Olee; Shawn P Grogan; Martin K Lotz; Clifford W Colwell; Darryl D D'Lima; Evan Y Snyder
Journal:  Tissue Eng Part A       Date:  2013-10-19       Impact factor: 3.845

2.  Biomaterials that regulate growth factor activity via bioinspired interactions.

Authors:  Gregory A Hudalla; William L Murphy
Journal:  Adv Funct Mater       Date:  2011-05-24       Impact factor: 18.808

Review 3.  Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.

Authors:  Mary C Farach-Carson; Curtis R Warren; Daniel A Harrington; Daniel D Carson
Journal:  Matrix Biol       Date:  2013-08-31       Impact factor: 11.583

4.  Deficiency in perlecan/HSPG2 during bone development enhances osteogenesis and decreases quality of adult bone in mice.

Authors:  Dylan A Lowe; Nadia Lepori-Bui; Peter V Fomin; Laura G Sloofman; Xiaozhou Zhou; Mary C Farach-Carson; Liyun Wang; Catherine B Kirn-Safran
Journal:  Calcif Tissue Int       Date:  2014-05-06       Impact factor: 4.333

5.  Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release.

Authors:  Amit K Jha; Weidong Yang; Catherine B Kirn-Safran; Mary C Farach-Carson; Xinqiao Jia
Journal:  Biomaterials       Date:  2009-09-23       Impact factor: 12.479

6.  HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses.

Authors:  Sonia D'Souza; Weidong Yang; Dario Marchetti; Caroline Muir; Mary C Farach-Carson; Daniel D Carson
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

7.  Soluble perlecan domain I enhances vascular endothelial growth factor-165 activity and receptor phosphorylation in human bone marrow endothelial cells.

Authors:  Arivalagan Muthusamy; Carlton R Cooper; Ronald R Gomes
Journal:  BMC Biochem       Date:  2010-11-03       Impact factor: 4.059

8.  Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation.

Authors:  A J Brown; M Alicknavitch; S S D'Souza; T Daikoku; C B Kirn-Safran; D Marchetti; D D Carson; M C Farach-Carson
Journal:  Bone       Date:  2008-06-06       Impact factor: 4.398

Review 9.  Heparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators.

Authors:  Kathryn D Rodgers; James D San Antonio; Olena Jacenko
Journal:  Dev Dyn       Date:  2008-10       Impact factor: 3.780

10.  Human primary corneal fibroblasts synthesize and deposit proteoglycans in long-term 3-D cultures.

Authors:  R Ren; A E K Hutcheon; X Q Guo; N Saeidi; S A Melotti; J W Ruberti; J D Zieske; V Trinkaus-Randall
Journal:  Dev Dyn       Date:  2008-10       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.